Bio-Thera: BAT1308 injection received notification of clinical trial

2020-05-28
|
ChinaPharma

Bio-Thera announced that on May 26, 2020, the company received the "Clinical Trial Notice" issued by the State Drug Administration regarding the company's drug BAT1308 injection.


BAT 1308 injection is a monoclonal antibody drug independently developed by Bio-Thera.


It can combine with PD-1 on the surface of T cells to release the inhibitory effect of PD-1 pathway on T cells, thereby restoring and improving the immune killer function of T cells and inhibiting tumor growth.


RELATED ARTICLES

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China
2020-09-02
|
Pharmaceutical , Medical care

Xuanzhu Biopharm closes RMB 800 mln Series A
2020-08-27
|
Pharmaceutical , PEVC

Anti-body R&D company Escugen closes Pre-A raising tens of millions in RMB
2020-08-27
|
PEVC , Biotech , Pharmaceutical

China's first COVID-19 vaccine produced by insect cells obtained clinical trial approval
2020-08-24
|
Pharmaceutical , Vaccine , Covid-19 , Biotech

D2M Biotherapeutics completes $10 million Pre-A round of financing
2020-08-23
|
PEVC , Pharmaceutical , Biotech

China's first mRNA Covid-19 vaccine approved for clinical trials
2020-06-29
|
Covid-19 , Biotechnology

New drug application of Paimpril accepted by State Drug Administration
2020-05-26
|
Biopharmaceutical , Medical care

Maccura Biotechnology's new coronavirus detection product obtains registration certificate
2020-05-18
|
Medical care , Pharmaceutical

Hengrui Medicine: Remazolam Tosylate for Injection Obtained Clinical Trial Notice
2020-05-14
|
Pharmaceutical
China SDG